Ankündigung • Apr 22
Vibrosense Dynamics AB Granted Patent in Japan on Biomarker for Prediction of Chemotherapy Induced Peripheral Neuropathy VibroSense Dynamics AB has been granted a patent in Japan on a Biomarker to predict the risk of developing permanent nerve damage caused by chemotherapy (CIPN) at treatment of cancer. The granted patent claims in Japan correspond to those previously granted by the European Patent Office (EPO). The patent strengthens the company's intellectual property protection and complements existing safeguards including encrypted algorithms in the software of the company's hand and foot instruments. CIPN are nerve damages caused by certain cytotoxic agents. It most commonly affects sensory nerves in the hands and feet, but can also cause motor and autonomic symptoms. CIPN is one of the most dose-limiting side effects in cancer therapy. Approximately 20-30% of patients receiving neurotoxic chemotherapy develop chronic nerve damage. Japan is one of the world's most cancer-affected nations, with among the highest incidences of gastric cancer, colorectal cancer and lung cancer globally. Lung cancer is the most common cancer in both the EU and Asia, especially among men. Smoking is the main risk factor. Breast cancer is the most common cancer in women globally. Incidence is increasing in both the Western world and parts of Asia, especially in urbanized areas. Colorectal cancer is the third most common cancer globally and is increasing in younger age groups, especially in Asia where Western diets are becoming more common. For these three cancers, the incidence is estimated1 to be around 5,600,000 new cases per year in the EU and Asia1. Ankündigung • Jan 15
Vibrosense Dynamics AB (publ) to Report Fiscal Year 2025 Results on Feb 13, 2026 Vibrosense Dynamics AB (publ) announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 13, 2026 Ankündigung • Sep 18
Vibrosense Dynamics AB (publ) to Report Q1, 2026 Results on Oct 17, 2025 Vibrosense Dynamics AB (publ) announced that they will report Q1, 2026 results on Oct 17, 2025 Ankündigung • Sep 10
VibroSense Dynamics AB (publ) Prepares for Launch in China VibroSense Dynamics AB (publ) enters the autumn with a strengthened organisation, new patent advancements, and preparations for the launch of VibroSense Meter II in China. On September 1st, company co-founder Toni Speidel assumed the role of CEO. Simultaneously, the marketing and sales team was strengthened with the addition of two new Marketing & Sales Specialists. To further support the company's expansion in China, a local Key Account Manager has also been appointed for the Chinese market. In May, the VibroSense meter®? II received approval from China's National Medical Products Administration (NMPA),marking a significant milestone that paves the way for entry into the large Chinese market. Further updates on the delivery status will be communicated at a later date. Meanwhile, China has recently introduced new restrictions on public procurement of medical devices from the EU. agreement with UMCare is not expected to be affected, as the contract value falls below the threshold of approximately EUR 5.3 million. However, the situation is being closely monitored. In parallel with the China expansion, VibroSense Dynamics continues to strengthen its market presence in Europe, including forming partnerships with clinics to conduct research on the VibroSense Meter II. Just before summer, a collaboration was initiated with the diabetic foot ulcer unit at the Complutense University of Madrid. The aim is to validate the VibroSense Meter™? II in clinical practice and compare the technology with current methods for diagnosing diabetic neuropathy. Another key milestone was receiving an Intention to Grant from the European Patent Office for a patent on a biomarker that can predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy. The patent will be valid for 20 years within the EU, and equivalent applications have been filed in the US, Japan, and China. With a strengthened organisation and ongoing market initiatives, VibroSense Dynamics is well-positioned to take the next step in its growth journey. Ankündigung • Aug 01
Vibrosense Dynamics AB Obtains Patent on Biomarker to Predict the Risk of Getting Nerve Damage During Cancer Treatment with Chemotherapy VibroSense Dynamics AB has received an Intention to Grant from the European Patent Office (EPO) regarding a patent on a Biomarker to predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy. The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer. The patent covers both the device and the method and strengthens the company's IP (Int intellectual Property) protection. In addition to patents, VibroSense Dynamics' products are protected by encrypted algorithms in the software of the VibroSense Meter®? II instrument. Ankündigung • Jul 24
Vibrosense Dynamics AB (publ) to Report Fiscal Year 2025 Results on Aug 22, 2025 Vibrosense Dynamics AB (publ) announced that they will report fiscal year 2025 results on Aug 22, 2025 New Risk • Jun 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (59% average daily change). Revenue is less than US$1m (kr2.8m revenue, or US$298k). Market cap is less than US$10m (kr64.5m market cap, or US$6.83m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding). Ankündigung • May 22
VibroSense Dynamics AB Receives NMPA Approval for VibroSense Meter II in China VibroSense Dynamics AB (publ) announced that its medical device, VibroSense Meter II, has been approved by the National Medical Products Administration (NMPA) in China. The approval marks a significant milestone in VibroSense Dynamics' global growth strategy and opens up new business opportunities in one of the world's fastest-growing medical technology markets. China currently has over 140 million people living with diabetes, creating a massive need for early diagnosis and monitoring of peripheral nerve damage - an area where VibroSense Meter II offers unique diagnostic precision. Reported Earnings • May 12
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr764.6k (up 62% from 3Q 2024). Net loss: kr1.23m (loss narrowed 44% from 3Q 2024). Ankündigung • Apr 10
Vibrosense Dynamics AB (publ) to Report Q3, 2025 Results on May 09, 2025 Vibrosense Dynamics AB (publ) announced that they will report Q3, 2025 results on May 09, 2025 Reported Earnings • Feb 07
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr848.3k (up 50% from 2Q 2024). Net loss: kr969.6k (loss narrowed 45% from 2Q 2024). Ankündigung • Jan 21
VibroSense Dynamics AB Receives European Patent on A Principle That Measures Skin Temperature Automatically and During an Examination VibroSense Dynamics AB has received a European patent on a principle that measures skin temperature automatically and wirelessly, before and during an examination, which ensures measurement quality. The patent is a so-called European patent (Unitary Patent) which has been extended by two additional countries. A Unitary Patent in the EU provides protection in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia, Sweden and Germany. In addition to these countries, the patent has also been approved and registered in the United Kingdom and Spain. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 2.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m (kr2.5m revenue, or US$227k). Market cap is less than US$10m (kr11.2m market cap, or US$1.00m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Ankündigung • Jan 09
Vibrosense Dynamics AB (publ) to Report Q2, 2025 Results on Feb 07, 2025 Vibrosense Dynamics AB (publ) announced that they will report Q2, 2025 results on Feb 07, 2025 Reported Earnings • Oct 02
Full year 2024 earnings released: kr0.41 loss per share (vs kr0.47 loss in FY 2023) Full year 2024 results: kr0.41 loss per share. Revenue: kr2.58m (up 42% from FY 2023). Net loss: kr7.67m (loss widened 3.2% from FY 2023). Ankündigung • Sep 29
Vibrosense Dynamics AB (publ) to Report Q1, 2025 Results on Oct 28, 2024 Vibrosense Dynamics AB (publ) announced that they will report Q1, 2025 results on Oct 28, 2024 Ankündigung • Aug 01
Vibrosense Dynamics AB (publ) to Report Fiscal Year 2024 Results on Aug 30, 2024 Vibrosense Dynamics AB (publ) announced that they will report fiscal year 2024 results on Aug 30, 2024 Ankündigung • Jul 17
Vibrosense Dynamics Appoints Tarik Cengiz as CEO VibroSense Dynamics announced that the organization by recruiting Tarik Cengiz as new CEO. Tarik will start his position as CEO on September 16, 2024 after he leaves his previous position as Global Sales Director at Arcoma AB. Tarik Cengiz will work with developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners. Tarik has deep knowledge of how healthcare works, both in Sweden and internationally. He also has experience in successfully driving international sales growth in small and medium-sized companies. Tarik has experience in identifying partners, negotiating agreements and then developing a fruitful collaboration for rapid growth. New Risk • Jun 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr7.4m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 2.4% per year over the past 5 years. Revenue is less than US$1m (kr2.1m revenue, or US$199k). Market cap is less than US$10m (kr23.1m market cap, or US$2.21m). Minor Risk Shareholders have been diluted in the past year (47% increase in shares outstanding). New Risk • Apr 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr7.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr7.4m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 2.4% per year over the past 5 years. Revenue is less than US$1m (kr2.1m revenue, or US$190k). Market cap is less than US$10m (kr24.2m market cap, or US$2.21m). Reported Earnings • Apr 19
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr473.5k (down 2.3% from 3Q 2023). Net loss: kr2.18m (loss widened 14% from 3Q 2023). Ankündigung • Mar 27
Vibrosense Dynamics AB (publ) to Report Q3, 2024 Results on Apr 12, 2024 Vibrosense Dynamics AB (publ) announced that they will report Q3, 2024 results on Apr 12, 2024 New Risk • Mar 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 1.5% per year over the past 5 years. Revenue is less than US$1m (kr2.1m revenue, or US$198k). Market cap is less than US$10m (kr27.6m market cap, or US$2.61m). Minor Risk Shareholders have been diluted in the past year (15% increase in shares outstanding). New Risk • Feb 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr104.3m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.5% per year over the past 5 years. Revenue is less than US$1m (kr2.1m revenue, or US$197k). Market cap is less than US$10m (kr104.3m market cap, or US$9.85m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Reported Earnings • Feb 11
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr565.3k (up 22% from 2Q 2023). Net loss: kr1.75m (loss narrowed 12% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Ankündigung • Jan 11
Vibrosense Dynamics AB (publ) to Report Q2, 2024 Results on Feb 09, 2024 Vibrosense Dynamics AB (publ) announced that they will report Q2, 2024 results on Feb 09, 2024 Ankündigung • Dec 20
VibroSense Submits Application for Regulatory Approval in China VibroSense Dynamics AB (publ) has submitted an application for regulatory approval for the Company's product VibroSense Meter®? II, to the Chinese authority National Medical Products Administration (NMPA). In February 2022, VibroSense signed an exclusive distributor agreement with the state-owned Chinese company Genertec Universal Medical Group (UMCARE). The agreement includes a commitment that UMCARE will assist VibroSense with the application for regulatory approval at NMPA. An approval required for UMCARE to sell the VibroSense meter®? II product with the application Diabetic Foot Screening in China. The agreement with UMCARE also includes a binding order of 3.8 MEUR that extends over three years, with fixed annual minimum calls, from the time of regulatory approval from NMPA. After a very extensive work, UMCARE has had the product VibroSense Meter™? II tested by a Chinese testing institute which has approved the product as a "medical device class II" in China. In the last step towards an approval, UMARE has now submitted a complete application to NMPA for review of all documentation with associated test protocols. NMPA is expected to report back within 2-3 months from today's date. The notice from the NMPA can either be a regulatory approval or a request for additional information. Ankündigung • Sep 28
Vibrosense Dynamics AB (publ) to Report Q1, 2024 Results on Oct 27, 2023 Vibrosense Dynamics AB (publ) announced that they will report Q1, 2024 results on Oct 27, 2023 Reported Earnings • Sep 03
Full year 2023 earnings released: kr0.43 loss per share (vs kr0.53 loss in FY 2022) Full year 2023 results: kr0.43 loss per share (improved from kr0.53 loss in FY 2022). Revenue: kr1.83m (up 24% from FY 2022). Net loss: kr7.43m (loss narrowed 6.9% from FY 2022). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Ankündigung • Sep 01
Vibrosense Dynamics AB (publ), Annual General Meeting, Sep 22, 2023 Vibrosense Dynamics AB (publ), Annual General Meeting, Sep 22, 2023. Ankündigung • Aug 03
Vibrosense Dynamics AB (publ) to Report Fiscal Year 2023 Results on Aug 31, 2023 Vibrosense Dynamics AB (publ) announced that they will report fiscal year 2023 results on Aug 31, 2023 Reported Earnings • Feb 12
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr475.0k (up 11% from 2Q 2022). Net loss: kr1.99m (loss narrowed 7.0% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Ankündigung • Jan 11
Vibrosense Dynamics AB (publ) to Report Q2, 2023 Results on Feb 09, 2023 Vibrosense Dynamics AB (publ) announced that they will report Q2, 2023 results on Feb 09, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Pontus Rehn was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr375.9k (up 25% from 1Q 2022). Net loss: kr1.44m (loss narrowed 7.1% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • Oct 07
Vibrosense Dynamics AB (publ) Announces Recognized Diabetes Clinic in Germany Evaluates VibroSense Meter II Vibrosense Dynamics AB (publ) announced that the diabetes clinic at the university hospital Klinikum Stuttgart evaluates the VibroSense Meter II, starting on October 11, 2022. A Research collaboration between the clinic and VibroSense Dynamics focusing on nerve damage in the feet caused by diabetes is also discussed. The diabetes clinic at Klinikum Stuttgart is a highly recognized clinic that treats people with diabetes type 1 or 2. The goal is to use the VibroSense Meter II and the application "Diabetic Foot Screening" as a standard examination of people with diabetes on the clinic. The clinic also works with research to study and develop effective methods for the care and treatment of the diabetic foot. Evaluation of "Diabetic Foot Screening" also includes a small research project in wherein the VibroSense Meter II will be used to assess Neuro-Sensory status in the diabetic foot. Reported Earnings • May 06
Third quarter 2022 earnings released: kr0.13 loss per share (vs kr0.11 loss in 3Q 2021) Third quarter 2022 results: kr0.13 loss per share (down from kr0.11 loss in 3Q 2021). Revenue: kr868.0k (up 99% from 3Q 2021). Net loss: kr1.92m (loss widened 27% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Pontus Rehn was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 13
Second quarter 2022 earnings: Revenues miss analyst expectations Second quarter 2022 results: Revenue: kr428.6k (up 154% from 2Q 2021). Net loss: kr2.14m (loss widened 1.9% from 2Q 2021). Revenue missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 15% per year. Ankündigung • Jan 13
VibroSense Dynamics AB Instrument VibroSense Meter® II Is Used in an Exploratory Clinical Study on Postural Orthostatic Tachycardia Syndrome VibroSense Dynamics AB instrument VibroSense Meter® II is used in an exploratory clinical study on Postural Orthostatic Tachycardia Syndrome. The purpose of the study is to investigate whether POTS also causes disorders in the peripheral nervous system. The ongoing clinical study is made on patients who have been diagnosed with POTS, which causes a primary disorder in the autonomic nervous system. All patients shall undergo additional clinical examinations for an assessment of neurology status and complete physical status. Professor Bodil Ohlsson at Scania University Hospital in Malmö is the principal investigator. The study aims to investigate whether POTS patients also have injuries/symptoms from the enteric and peripheral nervous system. The aim is to study the extent and connection between injuries in different parts of the peripheral nervous system and the autonomic nervous system. Ankündigung • Dec 31
VibroSense Dynamics AB Signs Registration Agreement with Genertec Universal Medical Group VibroSense Dynamics AB has signed an agreement with Genertec Universal Medical Group (UMCARE), to apply for registration of VibroSense Meter® II in the Chinese market. UMCARE estimate that there is a good possibility to obtain a regulatory approval and product registration in China within 12-18 months. The signed registration agreement is part of a recently started collaboration between VibroSense and UMCARE, to market and sell VibroSense Meter® II (VSM II) in China. After approved registration by the Chinese National Medical Products Administration (NMPA), VibroSense will hold full rights and certificates to market and sell VSM II in China. According to a preliminary review, VSM II will be classified as a Medical Device Class II in China. In parallel with the registration agreement, VibroSense and UMCARE are negotiating a distributor agreement, with the aim that UMCARE will receive the exclusive right to sell VSM II in China. The distributor agreement is planned to be signed no later than First Quarter 2022. Reported Earnings • Sep 02
Full year 2021 earnings released: kr0.52 loss per share (vs kr0.58 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: kr1.40m (up 14% from FY 2020). Net loss: kr7.16m (loss narrowed 1.6% from FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jul 23
Director recently bought kr140k worth of stock On the 19th of July, Antonio Speidel bought around 18k shares on-market at roughly kr8.01 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • May 18
Third quarter 2021 earnings released Third quarter 2021 results: Net loss: kr1.51m (loss narrowed 5.3% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • Mar 05
VibroSense Dynamics AB (publ) Applies for Patent on Biomarker to Predict the Risk of Nerve Damage Caused by Chemotherapy VibroSense Dynamics AB (publ) applied for patent on biomarker to predict the risk of nerve damage caused by chemotherapy. The result from a clinical pilot study, in collaboration with the clinic of Oncology at the university hospitals in Lund and Malmö as well as the hospital in Kristianstad, shows that VibroSense Meter and its technology can be used to predict the risk of getting permanent nerve damage caused by treatment of cancer with chemotherapy. The discovery is an important step to pave the way for a new biomarker that can support physicians within cancer treatment with chemotherapy. The patent application is based on a study conducted during 2018-2020, on patients with colorectal cancer treated with oxaliplatin-based drugs. The patients' sensitivity was examined with VibroSense Meter on hands and feet, before the first treatment and then during the ongoing treatment for 3-6 months. A follow-up examination with VibroSense Meter was performed 6 months after the last chemotherapy treatment. The results strongly indicate that it is possible to identify patients at high risk of acquiring permanent nerve damage 6 months after the final treatment, by measuring the patients' sensitivity with the VibroSense Meter before the first chemotherapy treatment. Is New 90 Day High Low • Feb 18
New 90-day low: kr7.78 The company is down 10.0% from its price of kr8.60 on 20 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period. Reported Earnings • Feb 13
Second quarter 2021 earnings released Second quarter 2021 results: Net loss: kr2.10m (loss widened 1.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Dec 30
New 90-day high: kr14.00 The company is up 79% from its price of kr7.84 on 30 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. Ankündigung • Dec 16
Vibrosense Dynamics AB (publ) Announces Diabetes Foot Screening Application Approved in Ongoing Validation Study and Ready for Market Launch VibroSense Dynamics AB (VibroSense) clinical validation study for the new application Diabetes Foot Screening, shows that the company's product VibroSense Meter® II meets all essential criteria for approval according to the clinical validation plan. VibroSense thus keeps the schedule the company has previously communicated and is ready to launch the Diabetes Foot Screening application to both primary and specialist care. During the fall of 2020, VibroSense Dynamics AB has conducted a clinical validation study with the new application Diabetes Foot Screening, designed for the company's product VibroSense Meter® II. The results of the study data obtained so far show that the application is approved according to the essential criteria set out in the clinical validation plan. The validation study includes patients with both type 1 and 2 diabetes, which conclude that the product VibroSense Meter® II can be sold to both primary and specialist care. This is an important milestone and means that the company can target both of these segments that make up the majority of the market in the diabetes indication area. Is New 90 Day High Low • Dec 01
New 90-day high: kr10.65 The company is up 40% from its price of kr7.60 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. Ankündigung • Oct 11
Vibrosense Dynamics AB (Publ) Presents Pilot Study Results with Use of VibroSense Meter® Ii At the scientific congress, Humanchwingungen in Würzburg Germany on October 1 2020, the result of a pilot study were presented in which the company's product VibroSense Meter® II was used. The aim of the study was to investigate short-term effects of exposure to hand-arm vibrations. The result showed a strong impact wherein a significant decrease of the sensitivity of fingers was detected with the VibroSense Meter® II. The data will become the basis for new recommendations for health controls of vibration-exposed personnel in Germany. The study result was presented by Dr. Alexandra Corominas from the Institute of Occupational and Environmental Medicine at Lübeck University Hospital (LIOH). The results showed a strong temporary deterioration of the sensitivity of the fingers at high frequencies after the subjects had been exposed to controlled low-frequency vibrations in the hand and arm. Based on the findings, the clinic has started a major study with the objective to provide recommendations and guidelines for regular health check-ups of vibration-exposed workers in Germany. The results from the study are very interesting for VibroSense. Not least considering that instrument, the VibroSense Meter® II has served as a relevant tool for detecting short-term effects caused by vibration exposure. Is New 90 Day High Low • Oct 08
New 90-day high: kr8.94 The company is up 33% from its price of kr6.74 on 10 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 15% over the same period. Ankündigung • Sep 17
VibroSense Dynamics AB Initiates Clinical Validation of Diabetes Foot Screening VibroSense Dynamics AB has started a clinical validation of the new Diabetes Foot Screening application in the product VibroSense Meter® II. Clinical validation is the final step before the product is ready for launch within the diabetes foot care segment. VibroSense Dynamics has in recent weeks started a clinical validation at Skåne University Hospital (SUS) of the new application Diabetes Foot Screening, which is the latest innovation in the instrument VibroSense Meter® II. The company follows the plan previously communicated and the clinical validation is the last phase prior to the commercial launch of the product within the Diabetes segment. The launch is expected to start in the later months of 2020. As part of the launch, targeted marketing and communication activities will be performed to approach main target groups in the Diabetes community. 